Home > Insider Trading > Filing (0001140361-12-023735)

Filing Details

Accession Number:: 0001140361-12-023735
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2012-05-08 17:56:35
Reporting Period:: 2012-05-04

Filing Date:: 2012-05-08
Accepted Time:: 2012-05-08 17:56:35
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1356576	Supernus Pharmaceuticals Inc	SUPN	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1291892	Ltd Management Abingworth	Princes House 38 Jermyn Street London X0 SW1Y 6DN		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, $0.001 Par Value Per Share	Acquisiton	2012-05-04	2,500,000	$0.00	2,500,000	No	4	C	Indirect	See Notes
Common Stock, $0.001 Par Value Per Share	Acquisiton	2012-05-04	1,100,000	$5.00	3,600,000	No	4	P	Indirect	See Notes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Notes
No	4	P	Indirect	See Notes

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Convertible Preferred Stock	Disposition	2012-05-04	10,000,000	$1.00	2,500,000	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	2006-02-14		No	4	C	Indirect

Footnotes

The 10,000,000 shares of Series A Convertible Preferred Stock, par value $0.001 per share ("Preferred Stock"), of Supernus Pharmaceuticals, Inc. (the "Issuer"), converted automatically into 2,500,000 shares of common stock, par value $0.001 per share ("Common Stock"), of the Issuer, without the payment to the Issuer of any consideration, upon the closing of the Issuer's initial public offering on May 4, 2012. The shares of Preferred Stock did not have an expiration date.
Abingworth Management LTD (the "Reporting Person") is the investment manager to a number of investment funds that include Abingworth Bioventures IV LP ("ABV IV") and Abingworth Bioventures IV Executives LP ("ABV IV Execs," and together with ABV IV, the "Abingworth Funds"). On May 4, 2012, ABV IV purchased 1,090,650 shares of Common Stock and ABV IV Execs purchased 9,350 shares of Common Stock.
Following the transactions reported herein, ABV IV holds 3,569,400 shares of Common Stock and ABV IV Execs holds 30,600 shares of Common Stock. The Reporting Person may be deemed to beneficially own the securities reported herein indirectly through the Abingworth Funds. The Reporting Person's interest in the securities reported herein is limited to the extent of its pecuniary interest, if any, in the Abingworth Funds. This report shall not be deemed an admission that the Reporting Person, either Abingworth Fund or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.